ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $52,635,122 | -17.6% | 1,476,441 | +6.7% | 1.41% | -7.2% |
| Q2 2023 | $63,856,329 | +19.2% | 1,384,269 | +3.6% | 1.52% | +18.8% |
| Q1 2023 | $53,589,680 | -10.4% | 1,336,401 | +3.6% | 1.28% | -11.1% |
| Q4 2022 | $59,778,626 | +21.5% | 1,290,279 | +8.6% | 1.44% | +13.1% |
| Q3 2022 | $49,195,000 | -24.6% | 1,187,992 | +8.7% | 1.27% | -33.0% |
| Q2 2022 | $65,210,000 | -12.7% | 1,093,030 | +6.3% | 1.90% | +1.0% |
| Q1 2022 | $74,661,000 | +0.4% | 1,028,109 | +16.3% | 1.88% | +9.4% |
| Q4 2021 | $74,329,000 | +2.9% | 883,921 | +10.3% | 1.72% | +13.0% |
| Q3 2021 | $72,252,000 | +63.0% | 801,109 | +72.3% | 1.52% | +73.4% |
| Q2 2021 | $44,338,000 | -13.5% | 465,000 | +3.3% | 0.88% | -21.6% |
| Q1 2021 | $51,237,000 | -34.7% | 450,000 | -20.6% | 1.12% | -32.8% |
| Q4 2020 | $78,421,000 | +65.4% | 566,500 | -1.8% | 1.66% | +38.2% |
| Q3 2020 | $47,411,000 | -6.3% | 576,841 | -10.8% | 1.20% | -13.3% |
| Q2 2020 | $50,596,000 | +52.3% | 646,841 | -13.5% | 1.39% | +1.0% |
| Q1 2020 | $33,225,000 | +11.1% | 747,800 | +6.8% | 1.37% | +45.4% |
| Q4 2019 | $29,897,000 | +14.9% | 700,000 | +15.1% | 0.94% | -8.8% |
| Q3 2019 | $26,010,000 | -29.4% | 608,000 | +4.8% | 1.04% | -22.2% |
| Q2 2019 | $36,830,000 | -8.4% | 580,000 | 0.0% | 1.33% | -14.1% |
| Q1 2019 | $40,229,000 | +117.7% | 580,000 | +36.5% | 1.55% | +77.9% |
| Q4 2018 | $18,479,000 | +21.0% | 425,000 | +112.5% | 0.87% | +57.7% |
| Q3 2018 | $15,268,000 | -0.7% | 200,000 | 0.0% | 0.55% | -6.6% |
| Q2 2018 | $15,374,000 | +74.3% | 200,000 | +15.6% | 0.59% | +57.4% |
| Q1 2018 | $8,821,000 | +16.7% | 173,000 | +6.1% | 0.38% | +9.6% |
| Q4 2017 | $7,560,000 | -12.9% | 163,000 | 0.0% | 0.34% | -14.2% |
| Q3 2017 | $8,681,000 | -12.9% | 163,000 | +1.6% | 0.40% | -20.5% |
| Q2 2017 | $9,969,000 | -7.9% | 160,500 | +0.5% | 0.50% | -19.5% |
| Q1 2017 | $10,828,000 | -3.6% | 159,750 | 0.0% | 0.62% | -16.9% |
| Q4 2016 | $11,232,000 | +7.7% | 159,750 | +8.7% | 0.75% | +15.0% |
| Q3 2016 | $10,428,000 | +50.7% | 147,000 | +3.9% | 0.65% | +27.7% |
| Q2 2016 | $6,921,000 | -7.7% | 141,500 | +19.4% | 0.51% | -18.6% |
| Q1 2016 | $7,502,000 | -36.6% | 118,500 | +12.3% | 0.63% | -29.9% |
| Q4 2015 | $11,835,000 | +14.8% | 105,500 | -1.4% | 0.90% | +7.3% |
| Q3 2015 | $10,305,000 | +9.4% | 107,000 | +16.3% | 0.84% | +21.5% |
| Q2 2015 | $9,420,000 | +64.9% | 92,000 | 0.0% | 0.69% | +28.8% |
| Q1 2015 | $5,712,000 | +83.4% | 92,000 | +29.6% | 0.53% | +46.7% |
| Q4 2014 | $3,115,000 | -18.5% | 71,000 | +5.2% | 0.36% | -38.4% |
| Q3 2014 | $3,821,000 | +30.0% | 67,500 | +3.1% | 0.59% | +12.1% |
| Q2 2014 | $2,940,000 | +16.8% | 65,500 | +27.2% | 0.53% | -9.3% |
| Q1 2014 | $2,518,000 | – | 51,500 | – | 0.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |